Recent Developments in the Maytansinoid Antitumor Agents
-
- Cassady John M.
- College of Pharmacy, The Ohio State University
-
- Chan Kenneth K.
- College of Pharmacy, The Ohio State University
-
- Floss Heinz G.
- Department of Chemistry, University of Washington
-
- Leistner Eckhard
- Institut für Pharmazeutische Biologie, Rheinische Wilhelms-Universität
Search this article
Abstract
Maytansine and its congeners have been isolated from higher plants, mosses and from an Actinomycete, Actinosynnema pretiosum. Many of these compounds are antitumor agents of extraordinary potency, yet phase II clinical trials with maytansine proved disappointing. The chemistry and biology of maytansinoids has been reviewed repeatedly in the late 1970s and early 1980s; the present review covers new developments in this field during the last two decades. These include the use of maytansinoids as “warheads” in tumor-specific antibodies, preliminary metabolism studies, investigations of their biosynthesis at the biochemical and genetic level, and ecological issues related to the occurrence of such typical microbial metabolites in higher plants.
Journal
-
- Chemical and Pharmaceutical Bulletin
-
Chemical and Pharmaceutical Bulletin 52 (1), 1-26, 2004
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679147949696
-
- NII Article ID
- 110003615471
-
- NII Book ID
- AA00602100
-
- DOI
- 10.1248/cpb.52.1
-
- ISSN
- 13475223
- 00092363
-
- NDL BIB ID
- 6794578
-
- PubMed
- 14709862
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed